Arbutus Biopharma Corpora...

3.48
-0.01 (-0.29%)
At close: Apr 01, 2025, 3:59 PM
3.48
-0.13%
After-hours: Apr 01, 2025, 05:57 PM EDT

Company Description

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States.

Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication.

The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.

It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc.

Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection.

The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015.

Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Arbutus Biopharma Corporation
Arbutus Biopharma Corporation logo
Country United States
IPO Date Jul 26, 2007
Industry Biotechnology
Sector Healthcare
Employees 44
CEO Lindsay Androski J.D., M.B.A.

Contact Details

Address:
701 Veterans Circle
Warminster, Pennsylvania
United States
Website https://www.arbutusbio.com

Stock Details

Ticker Symbol ABUS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001447028
CUSIP Number 03879J100
ISIN Number CA03879J1003
Employer ID 98-0597776
SIC Code 2834

Key Executives

Name Position
Lindsay Androski J.D., M.B.A. President, Chief Executive Officer & Chairman
Tuan Nguyen Chief Financial Officer
Lisa M. Caperelli Vice President of Investor Relations
R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C. Corporate Secretary
Shannon Briscoe SPHR Vice President of Human Resources

Latest SEC Filings

Date Type Title
Apr 01, 2025 4/A [Amend] Filing
Mar 31, 2025 4 Filing
Mar 31, 2025 3 Filing
Mar 27, 2025 10-K Annual Report
Mar 27, 2025 8-K Current Report
Mar 20, 2025 4 Filing
Mar 20, 2025 4 Filing
Mar 20, 2025 4 Filing
Mar 06, 2025 3 Filing
Mar 06, 2025 3 Filing